GlaxoSmithKline licenses SkyePharma formulation technology
UK drug delivery technology company SkyePharma has signed a licence agreement with GlaxoSmithKline to provide access to one of SkyePharma's proprietary formulation technologies for application to the delivery of respiratory drugs either by breath-actuated dry-powder inhaler or by metered-dose aerosol inhaler.
UK drug delivery technology company SkyePharma has signed a licence agreement with GlaxoSmithKline to provide access to one of SkyePharma's proprietary formulation technologies for application to the delivery of respiratory drugs either by breath-actuated dry-powder inhaler or by metered-dose aerosol inhaler.
GSK has made an initial payment to SkyePharma and if the patented formulation technology is subsequently incorporated into the company's current or future products, SkyePharma will be entitled to an additional payment for each such product and a royalty on eventual sales.
This new agreement comes in the wake of a recent FDA approvable letter for the Foradil CertiHaler that Sky Pharma codeveloped with Novartis and a subsequent second agreement with Novartis to jointly de-velop a dry-powder inhaler version of QAB149, a novel long-acting bronchodilator. There are now nine approved products incorporating three of SkyePharma's five technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities.